This MedLibrary.org supplementary page on Milrinone is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Milrinone
|
|
| Systematic (IUPAC) name | |
| 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H9N3O |
| Mol. mass | 211.219 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% (as IV bolus, infusion) |
| Protein binding | 70 to 80% |
| Metabolism | Hepatic (12%) |
| Half life | 2.3 hours |
| Excretion | Urine (85% as unchanged drug) within 24 hours |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status |
Rx Only |
| Routes | IV only |
Milrinone (Primacor) is a phosphodiesterase III inhibitor. It potentiates the effect of cyclic adenosine monophosphate (cAMP).
Milrinone also enhances relaxation of the left ventricle by increasing Ca2+-ATPase activity on the cardiac sarcoplasmic reticulum. This increases calcium ion uptake.
It has positive inotropic, vasodilating and minimal chronotropic effects. It is used in the management of heart failure only when conventional treatment with vasodilators and diuretics has proven insufficient. This is due to the potentially fatal adverse effects of milrinone, including ventricular arrhythmias.
Whereas beneficial hemodynamic effects are shown (at least short-term), several studies have shown no or a negative effect on mortality rates of hospitalized patients receiving milrinone.
One negative side to the use of milrinone is the prolonged half-life (2.5 hrs). This can result in a prolonged weaning and possible adverse outcomes from stopping this medication rapidly.
See also
External links
|
|||||||||||||||||
|
||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 14 August 2008, at 13:15.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Milrinone".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.